Janus Henderson Group PLC Elevation Oncology, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.26 - $3.94 $1.17 Million - $3.67 Million	-930,732 Reduced 83.86%	179,080 $250,000
Q1 2022 May 16, 2022	SELL	$2.34 - $6.41 $68,884 - $188,697	-29,438 Reduced 2.58%	1,109,812 $2.8 Million
Q4 2021 Feb 14, 2022	SELL	$4.15 - $8.86 $335,963 - $717,261	-80,955 Reduced 6.63%	1,139,250 $6.85 Million
Q3 2021 Nov 16, 2021	BUY	$7.66 - $16.11 $1.44 Million - $3.04 Million	188,517 Added 18.27%	1,220,205 $9.38 Million
Q2 2021 Aug 16, 2021	BUY	$11.44 - $13.57 $11.8 Million - $14 Million	1,031,688 New	1,031,688 $13.6 Million

45.4M

700

27.6K

Ticker ELEV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,300,900
Market Cap $16.3M
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.